Biomedicines Receives an Updated Impact Factor of 3.9 and CiteScore of 5.2

We are pleased to share that Biomedicines (ISSN: 2227-9059) was awarded an updated Impact Factor of 3.9 in the 2023 Journal Citation Reports™ released by Clarivate in June 2024, ranking in Q1 (85 among 354 titles) in the “Pharmacology and Pharmacy” category.

Additionally, according to data released by Scopus (Elsevier), Biomedicines received an increased CiteScore™ of 5.2, showing an increase of 40.5% compared to 2022.

Biomedicines’ CiteScore ranks as follows:

• Q2 (103 out of 398 journals) in the “Medicine (miscellaneous)” category;
• Q2 (74 out of 221 journals) in the “General Biochemistry, Genetics and Molecular Biology” category.

For further statistics, please visit https://www.mdpi.com/journal/biomedicines/stats. For more information about MDPI flagship journals' citation metrics, please see here.

At MDPI, our mission is simple, yet powerful—we strive every day to make scientific research freely accessible to everyone, everywhere. With over 3.5 million authors choosing MDPI, we have established ourselves as a key player driving the open access initiative.

Our journals have received over 13 million citations in the Web of Science, making us the most cited open access publisher. With over 800 institutional partners, MDPI continues to demonstrate its dedication to providing reliable and collaborative publishing services.

Biomedicines Editorial Office